Hexima

Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.

Investor

For information relating to investor updates, financial information, share trading and presentations click the link below.

Technology

Hexima is developing technology for use in transgenic plants to prevent damage by fungal pathogens and insect pests and for the treatment of fungal infections and non-melanoma skin cancer in humans.

Hexima receives approval to conduct a phase 1/2a study for fungal nail infections

Hexima Limited is pleased to announce today that it has received Human Research Ethics Committee approval to conduct a phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “Obtaining ethics approval for our first clinical trial is a major milestone for Hexima. It is the culmination of the last three years of work to generate the required non-clinical data including preclinical safety/toxicology, efficacy testing and manufacture, formulation and stability of HXP124. The ethics committee has reviewed this data, along with our clinical study design, and granted us permission to test this molecule on human patients for the first time. This is a critical step forward in the development of HXP124 as a treatment for fungal nail infections and we are very excited to begin this next phase of development.”

Updated: Upcoming CEO Presentations

Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.

Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).

Hexima Shareholder Update and Share Trading

Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo